Latest Industry Insights

Dr. Christian Landles explains why it is so challenging to develop therapeutics for rare diseases such as HD, and discusses the potential of approaches that target mutant huntingtin protein to improve treatment options for HD patients.

Dr. Christian Landles highlights some of the progress made in recent years to improve our understanding of HD and its drivers.

To learn more about NASH “in-a-box” and how it can help to advance drug discovery for NASH, Technology Networks spoke to Dr. Audrey Dubourg.

Technology Networks had the pleasure of interviewing Sunny Himansu M.B.B.S., D.SM – associate director, infectious diseases at Moderna – to discuss the biotech company's pipeline, how a collaboration with IAVI aims to make mRNA-based preventives and therapeutics globally accessible and the future of mRNA in medicine.

We spoke to Geoff Winkett and Michel van den Berge from Agilent, about the importance of fostering academia–industry relationships and how the issue of sustainability is shaping the way they approach the development of new and existing solutions.

The intricate and intertwined nature of the host‒microbiota connection has garnered increasing interest from the scientific community in recent years, due to its known role in the development and progression of various diseases. 4D pharma has leveraged growing knowledge in the field, by creating a novel class of medicines called live biotherapeutic products (LBPs).

In this interview, Jim Ross highlights several recent examples of how bioelectronic assays are helping to advance drug discovery for neurological diseases ranging from pediatric epilepsy to Burning Man Syndrome.

Emulate's chief scientific officer, Dr. Lorna Ewart, talks about inspiring a new generation of women in STEM.

Technology Networks interviewed Frank DeRosa, chief technology officer and head of research at the mRNA Center of Excellence, Sanofi, to discuss the “bright future” of mRNA platforms.

Technology Networks had the pleasure of interviewing Dr. Oliver Rinner, CEO at Biognosys, to learn more about some of the recent developments in proteomics, and discuss what the future could hold for the field.